Monday, October 5, 2026

Asus Introduces Ultra-Light Zenbook A16 with Powerful Snapdragon X2 Processor at CES 2023

Discover Asus's Zenbook A16: a 16-inch laptop lighter than a 13-inch MacBook Air, featuring Qualcomm's Snapdragon X2 for top performance and portability. Exp...

LM Salvado

February 3, 2026

Asus Introduces Ultra-Light Zenbook A16 with Powerful Snapdragon X2 Processor at CES 2023
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Asus has introduced its new Zenbook A16, a 16-inch laptop that weighs less than a 13-inch MacBook Air. This lightweight powerhouse is equipped with Qualcomm's Snapdragon X2 processor, offering impressive performance for its size and weight. According to The Verge AI, the Zenbook A16 was put through rigorous testing during CES, proving its capabilities even as pre-production hardware.

The Zenbook A16 aims to redefine the balance between portability and power in laptops. With its Snapdragon X2 processor, it promises to deliver high performance without compromising on battery life or size. This makes it particularly appealing to users who need a powerful device but also value mobility and convenience.

Asus sent a pre-production model of the Zenbook A16 to The Verge AI for testing. The device features the Snapdragon X2 Elite Extreme X2E-94-100 chip, which boasts 18 cores—six performance cores and 12 efficiency cores. The laptop is paired with 48GB of RAM and a 2TB SSD, providing ample storage and processing power. Additionally, it includes a 2880 x 1800 / 120Hz OLED display, ensuring a vibrant and responsive visual experience.

Despite being a pre-release model, the Zenbook A16 demonstrated solid performance during CES. The Snapdragon X2 processor handled multitasking efficiently, supporting numerous open applications including web browsers, productivity tools, and messaging apps. The laptop was also tested for photo editing tasks, showing remarkable speed when importing and processing large RAW images from a Sony A1 camera. While some issues arose, such as difficulties with Windows Hello face unlocking and occasional unexpected sleeps, these are expected to be resolved in the final release.

The implications of the Zenbook A16's capabilities are significant for both consumers and professionals. For consumers, this means having access to a lightweight yet powerful laptop that can handle everyday tasks with ease. For professionals, the Zenbook A16 offers a reliable tool for work that requires extensive multitasking and resource-intensive applications like photo editing. Its high-resolution display and efficient processor make it suitable for creative professionals who need a portable device that can keep up with demanding workflows.

Looking ahead, the Zenbook A16 is expected to compete directly with high-end models like the MacBook Air and MacBook Pro. With a potential price point of around $1,599.99 or $1,699.99, it positions itself as a competitive alternative in the market. Future updates to the hardware and software will likely address any remaining bugs and improve overall user experience. Keep an eye out for official reviews and benchmarks as the final version hits the market.

---

Source: [The Verge AI](https://www.theverge.com/tech/862985/asus-zenbook-a16-snapdragon-x2-ces-early-testing-hands-on)

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com